prostate biopsy Articles
-
An independent assessment of AI for prostate cancer detection - Case Study
Yale Medicine, an academic medical center with a high volume of prostate biopsies, conducted a study to determine Paige Prostate’s utility as a prescreening tool for clinical use. A total of 1,876 prostate core biopsy slides were analyzed by Paige Prostate, and only those cores categorized by the AI as “suspicious” or as out of distribution were manually reviewed by Yale ...
-
Validation of ClarityDX Prostate as a Reflex Test to Refine Prediction of Clinically Significant Prostate Cancer: ClinicalTrials.gov ID: NCT03957252
Summary This study is designed to determine the accuracy of the blood test ClarityDX Prostate to predict the results of prostate biopsies in men who have PSA (Prostate Specific Antigen) greater than 3 and no higher than 10 ...
-
Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men
Abstract Objective: To evaluate an epigenetic assay performed on tissue from negative prostate biopsies in a group of African American (AA) men undergoing repeat biopsy, and to compare accuracy for predicting repeat biopsy outcome to prior studies conducted in predominantly Caucasian populations. Materials and methods: The study population consisted of 211 AA men from 7 urology centers ...
By MDxHealth
-
Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment
Abstract Purpose: SelectMDx (MDxHealth®) is a panel of urinary biomarkers used in conjunction with traditional risk factors to individualize risk prediction for clinically significant prostate cancer. In this study we sought to characterize the effectiveness of SelectMDx in a population of American men with elevated prostate specific antigen. Materials and methods: We developed a ...
By MDxHealth
-
Bio-tech firm recruiting Yukon men for trial, Prostate cancer group says it could save lives
The Yukon chapter of Ride For Dad says a new blood test developed by an Alberta-based company could save the lives of men at risk of prostate cancer. (iStock/Getty Images) A bio-technology company based in Alberta is testing a new process that could result in fewer Yukon men travelling out of territory for prostate cancer biopsies. Private research company Nanostics Inc. and the University of ...
-
Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies
Abstract Background: Prostate cancer (PCa) diagnosis is challenging because efforts for effective, timely treatment of men with significant cancer typically result in over-diagnosis and repeat biopsies. The presence or absence of epigenetic aberrations, more specifically DNA-methylation of GSTP1, RASSF1, and APC in histopathologically negative prostate core biopsies has resulted in an ...
By MDxHealth
-
Nanostics Receives CE Mark for its ClarityDX Prostate Test to Detect Clinically Significant Prostate Cancer
Nanostics’ biomarker and machine learning-powered test, ClarityDX Prostate®, received a CE-IVD Mark. A CE-IVD Mark is required for all in vitro diagnostic (IVD) devices to be placed in the European Economic Area, Iceland, Norway, and Liechtenstein and allows Nanostics to market and sell ClarityDX Prostate® in these countries. The ClarityDX Prostate® test provides patients ...
-
Validation of a two-gene mRNA urine test for detection of high-grade prostate cancer in German men.
Organizations Martini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany, MDxHealth, B.V., Nijmegen, Netherlands, MDxHealth, Inc., Irvine, CA, Mathematical Modeling, Statistics and Bioinformatics, Ghent University, Ghent, Belgium, Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany Abstract ...
By MDxHealth
-
The Power of Digital Pathology: Why Labs Everywhere Should Make the Switch
Pathology as it is practiced today in labs around the world is not all that different from the pathology of the 19th century. The microscope has changed relatively little since then, and Hematoxylin and Eosin (H&E) stained slides remain the bread and butter of the pathologist. Yet it is not for lack of technological development; in recent years, digital pathology whole slide scanners, digital ...
-
Nanostics Announces Study Data Supporting ClarityDX Prostate as a Reflex Test to Predict Clinically Significant Prostate Cancer
Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. Using ClarityDX Prostate® as a reflex test vs. PSA test alone could have resulted in 37% fewer unnecessary biopsies. The clinical study recruited men from two sites in Alberta, Canada, and one site ...
-
Freehand Transperineal Biopsy
“Freehand transperineal biopsy” seems to be the latest buzzword in the urology world, and for good reason. Compared to transrectal, transperineal is proven to be the cleaner and ultimately safer approach for prostate biopsies. The support for transperineal is growing, as mounting evidence continues to debunk previous misconceptions of tolerability, feasibility and accuracy. We ...
-
Nanostics Re-Opens ClarityDX Prostate Clinical Study with New US Recruitment Site
Summary Nanostics' clinical validation study for ClarityDX Prostate, a liquid biopsy test for the early diagnosis of clinically significant prostate cancer, re-opens recruitment after lifting of COVID-19 research restrictions A top-ranked research institute in the Northeast US will now partner with Nanostics' by recruiting patients for the clinical validation study This partnership will ...
-
EDAP Announces Exclusive Worldwide Distribution Rights to Exact Imaging’s Micro-Ultrasound Technologies
Exact Imaging is a leading developer of ultra-high-resolution micro-ultrasound diagnostic technologies Micro-ultrasound ExactVu™ is the only ultrasound-based imaging tool with published data demonstrating prostate cancer diagnostic capabilities similar to MRI Combination of Exact Imaging’s micro-ultrasound and EDAP’s Focal One® represents the most complete offering for ...
-
How Has the COVID-19 Pandemic Affected Prostate Cancer Care?
#CancelEverything On March 11, 2020, the World Health Organization (WHO) declared the coronavirus 2019 disease (COVID-19) a global pandemic. Its impact left the world uncertain about health, politics and the economy. The first wave caused a major disruption to health services, exacerbating concerns of patient and physician safety and resource availability. On trend with the “cancel ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you